Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET
Company Participants
Sharon Klahre - Head, Investor Relations
Michael Metzger - Chief Executive Officer
Dr. Neil Gallagher - President and Head, R&D
Keith Goldan - Chief Financial Officer
Dr. Peter Ordentlich - Chief Scientific Officer
Dr. Anjali Ganguli - Chief Business Officer
Conference Call Participants
Anupam Rama - JPMorgan
Phil Nadeau - TD Cowen
Brad Canino - Stifel
Michael Schmidt - Guggenheim
Ashiq Mubarack - Citi
Kalpit Patel - B. Riley
Jeet Mukherjee - BTIG
Operator
Good day, everyone. And welcome to the Syndax Fourth Quarter and Full Year 2023 Earnings Conference Call. Today’s call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions]
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Sharon Klahre
Great. Thank you, Operator. Welcome and thank you all for joining us today for a view of Syndax’s fourth quarter and full year 2023 financial and operating results. I’m Sharon Klahre and with me this afternoon to provide an update on the company’s progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D; and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; and Dr. Anjali Ganguli, Chief Business Officer.
This call is accompanied by a slide deck that has been posted on the investor page of the company’s website. You can now turn to our forward-looking statements on slide two.
Before we begin, I’d like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in the company’s most recent annual report on Form 10-K, as well as other reports filed with the SEC.
Any forward-looking statements made represent our views as of today, February 27, 2024 only. A replay of this call will be available on the company’s website, www.syndax.com, following its completion.
With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax.